Navigation Links
Federal Regulation Will Require Renovators to Work Safely with Lead-Paint
Date:3/31/2008

Advocates Welcome Rule while Urging EPA to Fix Rule Flaws

WASHINGTON, March 31 /PRNewswire/ -- The Alliance for Healthy Homes and the National Center for Healthy Housing praise the new EPA regulation as a step in the right direction in saving children, workers and occupants from exposure to unhealthy levels of lead during renovation, repair, and painting activities in homes and child-occupied buildings built before 1978. At the same time, they say the rule must be strengthened to adequately protect children.

The rule requires contractors who work in older homes and child-occupied facilities to take simple, low-cost precautions to avoid creating and spreading lead dust, and to clean up any dust that is generated. The rule also requires the firms or management companies that are disturbing lead paint to be certified and to have at least one employee who has completed a one-day lead-safe work practices training. Firms are responsible for providing "on- the-job" training for all other employees. Power sanding, open flame burning, and sandblasting of painted surfaces is prohibited by the rule.

Although recent attention has been focused on lead in toys, the vast majority of children with lead poisoning are exposed to lead from the old paint in their own home. Dust created by damaged paint is the primary route of exposure for children. EPA estimates that as many as 8 million renovations occur each year that could generate dangerous levels of lead dust -- which even in miniscule amounts can harm children.

"Congress instructed the EPA to address the dangers of disturbing lead paint during renovations in 1992. In the 16 years since we've been waiting for this rule, at least 17 million children have been exposed to harmful levels of lead unnecessarily, permanently losing IQ points as a result. The new regulation is an important first step towards preventing another generation from being poisoned by debris left behind after a remodeling j
'/>"/>

SOURCE National Center for Healthy Housing
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. MDMA Names New Director of Federal Affairs
2. Federal research plan to determine nanotech risks fails to deliver
3. Federal Employee Program Maintains Low Health Premiums In 2008
4. AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States
5. SNM applauds NAS study showing need to restore federal nuclear medicine research funding
6. ACM Helps Medicaid Programs Comply With Federal Deficit Reduction Act Mandates
7. Boise(R) BEWARE(TM) Meets New Federal Guidelines Set Forth by Medicaid
8. HIV/AIDS Cases Among State and Federal Prison Inmates Fell for the Sixth Straight Year During 2005
9. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
10. Federal Trade Commission Attempts To Suppress Best-Selling Authors First Amendment Rights
11. CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 2A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 3A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 4A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8